FAGRFagron NV
23.90EUR+0.42%Mkt Cap: 1.79B EURP/E: 19.64Last update: 2026-05-14

Fagron NV, a pharmaceutical compounding company, delivers personalized pharmaceutical care to hospitals, pharmacies, clinics, patients, and worldwide. It operates through three segments: Essentials, Brands, and Compoundi…

loading…
Indicators:|

Key Statistics

Valuation
P/E (Trailing)19.64
P/E (Forward)14.79
PEG15.84
P/B3.23
P/S1.88
EV/EBITDA12.40
EV/Revenue2.18
EPS (TTM)1.24
EPS (Forward)1.65
Cash Flow & Leverage
FCF Yield4.68%
FCF Margin8.77%
Operating CF155.25M EUR
CapEx (TTM)30.61M EUR
Net Debt/EBITDA1.70
Net Debt284.23M EUR
Technical
SMA 5022.89 (+4.4%)
SMA 20021.57 (+10.8%)
Beta0.38
S&P 52W Chg24.23%
Avg Vol (30d)132.04K
Avg Vol (10d)108.07K
Technical Indicators
RSI (14)54.4
MACD0.3485
MACD Signal0.4513
MACD Hist.-0.1028
BB Upper24.82 EUR
BB Middle24.06 EUR
BB Lower23.30 EUR
BB Width6.30%
ATR (14)0.5000 EUR
Vol Ratio (20d)2.11x
52W Range
19.2480% of range25.05
52W High25.05 EUR
52W Low19.24 EUR
Profitability
Gross Margin45.37%
EBITDA Margin17.55%
Profit Margin9.56%
Oper. Margin15.08%
ROE16.50%
ROA7.32%
Revenue Growth7.60%
Earnings Growth12.70%
Balance Sheet
Debt/Equity0.85
Current Ratio2.11
Quick Ratio1.39
Book Value/Sh7.531 EUR
Cash/Share2.525 EUR
Dividends
Fwd Div Rate0.4000 EUR
Trail. Div Rate0.4000 EUR
Div. Yield1.64%
5Y Avg Yield1.45%
Payout Ratio28.23%
Ex-Div DateMay 18, 2026
Pay Date
Ownership
Shares Out.73.35M
Float65.76M
Insiders0.30%
Institutions68.46%
Analyst Consensus
Rating
Target (Mean)28.25 EUR
Target Range27.00 EUR30.00 EUR
# Analysts6
Company
Market Cap1.79B EUR
Enterprise Value2.07B EUR
Revenue (TTM)952.17M EUR
Gross Profit432.00M EUR
Net Income (TTM)91.02M EUR
Revenue/Share13.03 EUR
Fiscal Year EndDec 2025
MR QuarterDec 2025
Employees4.2K
Last Price23.90 EUR
CountryBE
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISINBE0003874915